Seres Therapeutics (MCRB) Operating Leases: 2019-2025
Historic Operating Leases for Seres Therapeutics (MCRB) over the last 7 years, with Sep 2025 value amounting to $75.3 million.
- Seres Therapeutics' Operating Leases fell 11.65% to $75.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year decrease of 11.65%. This contributed to the annual value of $83.0 million for FY2024, which is 9.48% down from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' Operating Leases is $75.3 million, which was down 3.36% from $78.0 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Operating Leases ranged from a high of $107.9 million in Q4 2022 and a low of $9.2 million during Q1 2021.
- Over the past 3 years, Seres Therapeutics' median Operating Leases value was $91.7 million (recorded in 2023), while the average stood at $92.4 million.
- Per our database at Business Quant, Seres Therapeutics' Operating Leases tumbled by 36.35% in 2021 and then soared by 501.08% in 2022.
- Over the past 5 years, Seres Therapeutics' Operating Leases (Quarterly) stood at $18.0 million in 2021, then surged by 501.08% to $107.9 million in 2022, then fell by 15.09% to $91.7 million in 2023, then fell by 9.48% to $83.0 million in 2024, then dropped by 11.65% to $75.3 million in 2025.
- Its Operating Leases stands at $75.3 million for Q3 2025, versus $78.0 million for Q2 2025 and $80.5 million for Q1 2025.